Incorporating Immunotherapy in the Treatment of Early-Stage Bladder Cancer

February 6, 2019
Arjun V. Balar, MD

Arjun V. Balar, MD, discusses a few approaches for incorporating immunotherapy treatments into the frontline for patients with bladder cancer.

Arjun V. Balar, MD, assistant professor in the Department of Medicine and director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center, discusses a few approaches for incorporating immunotherapy treatments for patients with early-stage bladder cancer.

There is a major interest in using these therapies in the earlier setting, according to Balar. There are currently ongoing trials for stage II bladder cancer in either the perioperative setting, adjuvant setting, or in combination with chemotherapy and radiation in lieu of surgery.